Phase II Study of YM060 - Double-blind, Parallel-group Comparative Study in Patients (Female) With Diarrhea-predominant Irritable Bowel Syndrome

NCT01274000 Phase 2 COMPLETED

A study to verify the superiority of YM060 (ramosetron) to placebo for female patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.

Details

Lead sponsor	Astellas Pharma Inc
Phase	Phase 2
Status	COMPLETED
Enrolment	409
Start date	2010-11
Completion	2011-10

Conditions

• Irritable Bowel Syndrome

Interventions

• YM060
• placebo

Primary outcomes

• Responder rate of patients reported global assessment of relief of IBS symptoms — for 4 weeks

Countries

Japan